DETAILED ACTION
Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
Continued Examination Under 37 CFR 1.114
A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 30 December 2024 has been entered.
Status of the Claims
Claims 1, 2, 4-6, and 29-41 are pending.
Claims 29-34 are withdrawn from consideration as directed to non-elected inventions.
Claims 1, 2, 4-6, and 35-41 are presented for examination and rejected as set forth below.
Response to Amendment
The third declaration of the Inventor Dr. Hu under 37 CFR 1.132 filed 30 December 2024 is insufficient to overcome the rejection of Claims 1, 2, 4-6, and 35-40 based upon the teachings of Hu, either alone or in combination with Adil as set forth in the last Office action because the declarant’s opinion fails to overcome the rejections of record, and the data provided fail to properly establish evidence of secondary indicia of nonobviousness.
Dr. Hu’s assertion that the Hu reference refers only to the treatment of hepatotoxicity is contradicted by the actual text of the Hu reference, which establishes not only that hepatotoxicity caused by APAP overdose is treatable by the administration of any selection or combination of mannitol, sucralose, EUDRAGIT S100, and PLURONIC F68 as recited by the present claims, but also that the acute renal failure and renal damage of the instant claims arises from hepatorenal syndrome brought on by acetaminophen toxicity which can also be avoided by the administration of any selection or combination of mannitol, sucralose, EUDRAGIT S100, and PLURONIC F68 taught as effective in the treatment of hepatotoxicity. As such, the Hu reference establishes that the presently claimed preventing, reducing, or eradication of nephrotoxicity or the recovery of renal function caused by acetaminophen overdose by the administration of any selection or combination of mannitol, sucralose, EUDRAGIT S100, and PLURONIC F68 would be expected to result from the administration of the agents claimed to the patient population designated. To the inventor-declarant’s position that that hepatotoxicity and nephrotoxicity can be more complex, can arise from distinct mechanisms or different etiologies, or can happen separately is immaterial to the fact that the Hu reference teaches the limitations of the claims which have been presented.
Dr. Hu again repeats their assertion that certain embodiments of the methods claimed present evidence of synergy. This remains unpersuasive as unsupported by appropriate objective evidence. While BUN and creatinine data concerning the administration of four combinations of components recited by the instant claims are provided, there remains nothing of record to establish what, if anything, these combinations are superior to. Once the examiner establishes a prima facie case of obviousness, the burden shifts to the applicant to rebut that case. In re Kao, 639 F.3d 1057, 1066 (Fed. Cir. 2011). “[A]ppellants have the burden of explaining the data…they proffer as evidence of non-obviousness.” Ex parte Ishizaka, 24 USPQ2d 1621, 1624 (Bd. Pat. App. & Inter. 1992). The evidence relied upon should establish “that the differences in results are in fact unexpected and unobvious and of both statistical and practical significance.” Ex parte Gelles, 22 USPQ2d 1318, 1319 (Bd. Pat. App. & Inter. 1992). Here, the six graphs asserted as establishing evidence of synergy in the reduction of creatinine or BUN, S1-S6, fail to provide any control data, such as by comparing the combinations of therapeutic components to the results obtained by the components individually in relation to some external control. Particular significance concerning non-obviousness cannot be ascribed to those examples since the procedures followed in the two examples do not have such correspondence that the improved results can be traced, within a reasonable certainty, to the combination tested alone. It is not an unreasonable burden on applicants to require comparative examples relied on for non-obviousness to be truly comparative. The cause and effect sought to be proven is lost here in the welter of unfixed variables. In re Dunn, 349 F.2d 433, 439 (CCPA 1965). This is particularly critical when the declarant’s assertion of a synergistic reduction in each of creatinine and BUN are considered: there is literally no data provided which would permit a skilled artisan to ascertain the degree to which creatinine or BUN has been decreased, which therefore makes it impossible for the skilled artisan to determine whether the asserted reduction in each of creatinine and BUN represent a subadditive, additive, or supraadditive effect on each of these biomarkers. Further complicating the veracity of the declarants position is the fact that in none of the assessments provided are identical doses of each of the tested agents compared. Because of this absence of context and the lack of an appropriate point of comparison, Dr. Hu’s discussion of results observed with six specific combinations falling within the scope of the invention claimed is unpersuasive. See Kao, supra, at 1068 (Applicants must “provide an adequate basis to support the conclusion that other embodiments falling within the claim will behave in the same manner” in order to “establish that the evidence is commensurate with [the] scope of the claims.”).
On the basis of the record, then, it cannot reasonably be said that the instant claims provide anything that a skilled artisan would not expect to see regarding renal toxicity from the administration of any of the mannitol, sucralose, menthol, EUDRAGIT S100, and PLURONIC F68 of the instant claims, nor of the NAC known as an alternative APAP overdose treatment in the prior art.
Claim Interpretation
Applicants Claims are directed towards methods of “preventing, reducing, or eradicating toxicity caused by acetaminophen” by administering any of a variety of compounds. These compounds include, among others, each of poly(methacrylic acid-methyl methacrylate) (also known as EUDRAGIT copolymers), polyoxyethylene-polyoxypropylene clock copolymers (known as, among others, PLURONIC copolymers), sucralose, mannitol, luteolin, or kaempferol. These compounds are administered in “amount[s] effective in preventing, reducing, or eradicating nephrotoxicity caused by APAP or its derivative,” or are directed to recovering renal function and reducing renal lesions caused by APAP overdose by administering amounts of the compounds selected to achieve those outcomes. Applicants are reminded that a “whereby clause in a method claim is not given weight when it simply expresses the intended result of a process step positively recited.” Hoffer v. Microsoft Corp., 405 F.3d 1326, 1329, 74 USPQ2d 1481, 1483 (Fed. Cir. 2005) (quoting Minton v. Nat’l Ass’n of Securities Dealers, Inc., 336 F.3d 1373, 1381, 67 USPQ2d 1614, 1620 (Fed. Cir. 2003)). Attention is drawn to Applicants’ disclosure, paragraph [0047], which indicates that “various antidote agents each at dose of less than or equivalent to 200mg per 60kg person body weight of single dose administration”; the Examiner considers art addressing either this range of dosages or which explicitly describe preventing, reducing, or eradicating toxicity associated with acetaminophen as suitable for addressing the functionally defined limitations of antidote concentrations. Dependent claims narrow the listing of compounds used in the method claimed, or add a second component to the compositions used in the methods recited. Dependent Claims narrow the scope of required compounds administered to combat such toxicity to, for example, combinations of either of EUDRAGIT S100 or PLURONIC F68 combined with sucralose or mannitol, or a combination of mannitol and sucralose.
Claim Rejections - 35 USC § 102
In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status.
The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:
A person shall be entitled to a patent unless –
(a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention.
Claims 1, 5, 35, and 36 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Hu (EP3069733)(13 Aug 2020 IDS FOR REF 1).
Hu indicates that acetaminophen overdose follows a predictable course with the degree of damage to the liver, as well as subsequent renal damage, and the prognosis of such overdose being readily determinable by “stage 3,” usually occurring 3-4 days following the administration of the toxic dose of acetaminophen. [0003]. Hu teaches that stage 4 acetaminophen intoxication causes renal failure, (id.), that severe renal toxicity is attributable to the direct metabolism of APAP in P-450s, as well as the fact that acute renal failure and renal damage of Claims 35 and 36 arise from hepatorenal syndrome brought on by acetaminophen toxicity. [0004]. Hu describes the administration of each of mannitol and sucralose, and combinations of mannitol and sucralose, to reduce acetaminophen hepatotoxicity in rats, which by the teaching of Hu would reduce or prevent nephrotoxicity which such liver damage would cause, addressing the limitations of instant Claims 1, 3, 5, 23, 35, and 36. [0035] “Table 1.”
Claim Rejections - 35 USC § 103
The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action:
A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made.
The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows:
1. Determining the scope and contents of the prior art.
2. Ascertaining the differences between the prior art and the claims at issue.
3. Resolving the level of ordinary skill in the pertinent art.
4. Considering objective evidence present in the application indicating obviousness or nonobviousness.
This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention.
Claims 1, 2, 4-6, and 35-41 are rejected under 35 U.S.C. 103 as being unpatentable over Hu (EP3069733).
Hu describes compositions for use in alleviating liver toxicity (the “hepatotoxicity of instant claim 3), as well as renal damage which follows (the “nephrotoxicity” of Claims 1 and 3) of acetaminophen by the administration of any of a variety of pharmaceutically acceptable excipients including each of the instantly claimed mannitol, sucralose, EUDRAGIT S100, and PLURONIC F68. (Abs.), [0013]. Hu indicates that pharmaceutically acceptable combinations of acetaminophen and compounds which inhibit the activity of CYP2E1 in the liver are particularly useful in combatting the hepatotoxicity produced by over administration of acetaminophen. [0004-07; 0011-12]. Hu describes effective dosages for reducing such hepatotoxicity for each of the above recited and instantly claimed compounds as, for example, between about 0.01-5.5g mannitol, between about 0.1-5.5g sucralose, between about 0.17-5.5g EUDRAGIT S100, and between about 1.0-5.5g PLURONIC F68.
It would have been prima facie obvious to have combined acetaminophen with any of mannitol, sucralose, EUDRAGIT S100, PLURONIC F68, and combinations thereof, or indeed any of the combinations of EUDRAGIT S100 with either mannitol or sucralose, or PLURONIC F68 with either mannitol or sucralose, to provide a composition suitable for reducing the likelihood of suffering hepatotoxicity caused by acetaminophen as set forth by the instant claims. One having ordinary skill in the art would have been motivated to do so because Hu establishes that each of the instantly claimed mannitol, sucralose, EUDRAGIT S100, and PLURONIC F68 are known to reduce hepatotoxicity caused by administration of acetaminophen. Hu also teaches combining acetaminophen with any of the instantly claimed mannitol, sucralose, EUDRAGIT S100, and PLURONIC F68 to achieve this end. Furthermore, concerning the combinations of antidote elements set forth by each of Claims 6 and 24, these combinations amount to little more than combinations of two compositions, each of which is taught by the prior art to be useful for the same purpose, in order to form a third composition to be used for the very same purpose. The idea for combining them flows logically from their having been individually taught in the prior art. In re Kerkhoven, 626 F.2d 846, 850, 205 USPQ 1069, 1072 (CCPA 1980).
Double Patenting
The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).
A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b).
The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/process/file/efs/guidance/eTD-info-I.jsp.
Claims 1, 2, 4-6, and 35-41 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-4 of U.S. Patent No. 10,420,737 in view of Hu and Adil discussed in greater detail above. Although the claims at issue are not identical, they are not patentably distinct from each other because the ‘737 claims combine acetaminophen and each of mannitol and sucralose to provide compositions for reducing hepatotoxicity. As Hu establishd, above, each of the additional components EUDRAGIT S100 and PLURONIC F6 are also known to be useful in combatting acetaminophen-induced hepatotoxicity, which in turn causes nephrotoxicity of the instant claims, making their combination prima facie obvious. See Kerkhoven, supra.
Claims 1, 2, 4-6, and 35-41 are provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1, 2, 4-6, 14-29, and 31-35 of copending Application No. 16/411,861 (reference application) in view of Hu discussed in greater detail above. Although the claims at issue are not identical, they are not patentably distinct from each other because the copending ‘961 claims set forth various combinations of the mannitol, sucralose, EUDRAGIT S100, and PLURONIC F6 of the instant claims as suitably reducing liver toxicity resulting from the administration of acetaminophen. See Kerkhoven, supra. As Hu establishes that hepatoxicity caused by APAP overdose leads to renal toxicity of the instant claims, this too is an obvious permutation of the copending claims.
This is a provisional nonstatutory double patenting rejection because the patentably indistinct claims have not in fact been patented.
Response to Arguments
Applicant's arguments filed 30 December 2024 have been fully considered but they are not persuasive.
The impact of the third Hu declaration has been addressed above and will not be reiterated: applicant arguments based on the third Hu declaration are unpersuasive for the reasons set forth above.
Applicants assertions that the claims are not anticipated by Hu are unpersuasive. To reiterate, Hu teaches that stage 4 acetaminophen intoxication causes renal failure, [0003], that severe renal toxicity is attributable to the direct metabolism of APAP in P-450s, as well as the fact that acute renal failure and renal damage of Claims 35 and 36 arise from hepatorenal syndrome brought on by acetaminophen toxicity. [0004]. Hu describes the administration of each of mannitol and sucralose, and combinations of mannitol and sucralose, to reduce acetaminophen hepatotoxicity in rats, which by the teaching of Hu would reduce or prevent nephrotoxicity which such liver damage would cause, addressing the limitations of instant Claims 1, 3, 5, 23, 35, and 36. [0035].
Applicants assertion that the claims are nonobvious over Hu are unpersuasive, as applicants advance no substantive argument concerning the examiner’s prima facie case other than a sidelong reference to modifications that can be made are insufficient absent a rationale for modifying the art in such a manner. The record is replete with the examiner’s articulation, supported by both objective evidence and sound reasoning, setting forth the exact rationale required by prevailing caselaw. As set forth in greater detail above, Applicants offer no persuasive evidence of secondary indicia of nonobviousness, so this assertion too must fail.
The double patenting rejections are maintained for the reasons set forth above, applicants arguments paralleling those set forth concerning the obviousness of the claims presented and unpersuasive for the same reasons.
For at least these reasons, applicants arguments are unpersuasive.
Conclusion
No Claims are allowable.
All claims are identical to or patentably indistinct from, or have unity of invention with claims in the application prior to the entry of the submission under 37 CFR 1.114 (that is, restriction (including a lack of unity of invention) would not be proper) and all claims could have been finally rejected on the grounds and art of record in the next Office action if they had been entered in the application prior to entry under 37 CFR 1.114. Accordingly, THIS ACTION IS MADE FINAL even though it is a first action after the filing of a request for continued examination and the submission under 37 CFR 1.114. See MPEP § 706.07(b). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).
A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.
Any inquiry concerning this communication or earlier communications from the examiner should be directed to SEAN M BASQUILL whose telephone number is (571)270-5862. The examiner can normally be reached Monday through Thursday, 5:30 AM to 4 PM.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Ali Soroush can be reached on (571) 272-9925. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/SEAN M BASQUILL/Primary Examiner, Art Unit 1614